StockData

IRulya Therapeutics Inc. (IRLA) stock

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$39.80+0.02 (+0.05%)

Close on Nov 13, 2026Market cap $40.48MP/E –Yield –

IRulya Therapeutics total assets

Total assets on the balance sheet at the end of each period.

IRulya Therapeutics's total assets was $106.47M at Sep 30, 2026. For fiscal 2025 it was $93.52M, down 18.3% from the year before. The highest annual figure on record is $189.47M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$93.52M-18.3%
FY2024Dec 31, 2024$114.48M-31.8%
FY2023Dec 31, 2023$167.90M+61.6%
FY2022Dec 31, 2022$103.91M-22.0%
FY2021Dec 31, 2021$133.23M-29.7%
FY2020Dec 31, 2020$189.47M+52.3%
FY2019Dec 31, 2019$124.37M+70.7%
FY2018Dec 31, 2018$72.88M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$106.47M-3.1%
Q2 FY2026Jun 30, 2026$124.00M+5.8%
Q1 FY2026Mar 31, 2026$26.62M-75.1%
Q4 FY2025Dec 31, 2025$93.52M-18.3%
Q3 FY2025Sep 30, 2025$109.90M-13.1%
Q2 FY2025Jun 30, 2025$117.21M-13.1%
Q1 FY2025Mar 31, 2025$107.09M-32.8%
Q4 FY2024Dec 31, 2024$114.48M-31.8%
Q3 FY2024Sep 30, 2024$126.52M+48.2%
Q2 FY2024Jun 30, 2024$134.83M+51.8%
Q1 FY2024Mar 31, 2024$159.29M+70.7%
Q4 FY2023Dec 31, 2023$167.90M+61.6%
Q3 FY2023Sep 30, 2023$85.39M-22.2%
Q2 FY2023Jun 30, 2023$88.84M-24.6%
Q1 FY2023Mar 31, 2023$93.32M-19.6%
Q4 FY2022Dec 31, 2022$103.91M-22.0%
Q3 FY2022Sep 30, 2022$109.78M-25.5%
Q2 FY2022Jun 30, 2022$117.86M-27.0%
Q1 FY2022Mar 31, 2022$116.13M-33.5%
Q4 FY2021Dec 31, 2021$133.23M-29.7%
Q3 FY2021Sep 30, 2021$147.42M-28.0%
Q2 FY2021Jun 30, 2021$161.39M-26.4%
Q1 FY2021Mar 31, 2021$174.52M-24.5%
Q4 FY2020Dec 31, 2020$189.47M+52.3%
Q3 FY2020Sep 30, 2020$204.66M+53.4%
Q2 FY2020Jun 30, 2020$219.21M+53.0%
Q1 FY2020Mar 31, 2020$231.21M+227.5%
Q4 FY2019Dec 31, 2019$124.37M+70.7%
Q3 FY2019Sep 30, 2019$133.41M–
Q2 FY2019Jun 30, 2019$143.24M–
Q1 FY2019Mar 31, 2019$70.60M–
Q4 FY2018Dec 31, 2018$72.88M–

More IRulya Therapeutics figures

See a number that looks wrong?